Efficacy and Safety of Anti-Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab in Neonates: A Real-World Monocentric Study
Vaccines (Basel). 2025 Aug 6;13(8):838. doi: 10.3390/vaccines13080838. ABSTRACT BACKGROUND: RSV remains a leading cause of infant hospitalization worldwide, and the recently approved nirsevimab could represent …